Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHA-O
- Development stage
- Preclinical
- Lead developer
- DSM-Firmenich
- Administration
- Oral
01
Overview
DHA-O is a dietary supplement developed by DSM Nutritional Products, Inc. for the purpose of investigating its efficacy and safety in lowering elevated triglyceride levels in healthy adults with hypertriglyceridemia. Its active component, docosahexaenoic acid (DHA), is an omega-3 fatty acid known to reduce plasma triglyceride levels through multiple mechanisms, including the activation of peroxisome proliferator-activated receptor alpha (PPARα), suppression of hepatic lipogenesis and very-low-density lipoprotein (VLDL) production, and enhancement of lipoprotein lipase (LPL) activity. Additionally, DHA-derived N-acyl taurines may inhibit intestinal triglyceride absorption.
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on DHA-O.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHA-O.